The increased expression of receptor activator of nuclear-κB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate

Journal of Cellular Biochemistry

Volumn 111, Issue 1, 2010, Pages 130-137

  Fernández, Mireya ^a   Pino, Ana M ^a   Figueroa, Paula ^a   Rodríguez, Juan P ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Bisphosphonates; Human mesenchymal stromal cells; Ibandronate; Multiple Myeloma; RANKL expression

Indexed keywords

IBANDRONIC ACID; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; BONE MARROW CELL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; UPREGULATION; WESTERN BLOTTING;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; CELLS, CULTURED; DIPHOSPHONATES; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MULTIPLE MYELOMA; RANK LIGAND; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 77957143607     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22676     Document Type: Article

References (50)

1. Barrett J, Worth E, Bauss F, Epstein S. 2004. Ibandronate: A clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44:951-965. (Pubitemid 39096810)
2. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandre C. 1991. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of humanmultiplemyeloma. J Clin Invest 88:62-66.
3. Boyle Wl, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
4. Breitkreuz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D, Okawa Y, Munshi NC, Richardson PG, Anderson KC. 2008. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22:1925-1932.
5. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL. 1999. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538.
6. Clézardin P, Ebetino FH, Fournier PGJ. 2005. Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity. Cancer Res 65:4971-4974. (Pubitemid 40827299)
7. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. 2001. Receptor activator of NF-KB ligand and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276:20659-20672.
8. Cruz JC, Alsina M, Craig F. 2001. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol 29:441-447.
9. Derenne S, Amiot M, Barillé S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R. 1999. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14:2048-2056.
10. Fan X, Roy E, Zhu L, Murphy TC, Ackert-Bicknel C, Hart CM, Rosen C, Nanes MS, Rubin J. 2004. Nitric oxide regulates RANKL and OPG expression in bone marrow stromal cell. Endocrinology 145:751-759.
11. Feng X, Teitelbaum SL, Quiroz M, Cheng S-L, Lai C-F, Avioli LV, Ross FP. 2000. Sp1/Sp3 and PU.1 differentially regulate b5 integrin gene expression in macrophages and osteoblasts. J Biol Chem 275:8331-8340. (Pubitemid 30180173)
12. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. 1999. Alendronate mechanism of action: Geranyl geraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138. (Pubitemid 29036065)
13. Fleisch H. Bisphosphonates: Mechanism of action.1998. Endocr Rev19:80-100.
14. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. 2001. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527-3533.
15. Guise TA. Antitumor effects of bisphosphonates: Promising preclinical evidence. 2008. Cancer Treat Rev 34(Suppl 1): S19-S24.
16. Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, Possinger K, Hofbauer LC, Sezer O. 2003. Expression of receptor activator factor KB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 9:1436-1440.
17. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC. 2006. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107:4053-4062.
18. Hofbauer L, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. 1999. Interleukin 1-β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255-259. (Pubitemid 29406050)
19. Jilka RL. 1998. Cytokines, bone remodelling, and estrogen deficiency. A 1998 update. Bone 23:75-81.
20. Kearns AE, Khosla S, Kostenuik PJ. 2008. Receptor activator of nuclear factor kB ligand and osteoprtegerin regulation of bone remodelling in health and disease. Endocrin Rev 29:155-192.
21. Lee MV, Fong EM, Singer FR, Guenette RS. 2001. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61:2602-2608. (Pubitemid 32685845)
22. Lee SK, Kalinowski J, Jastrzebski S, Lorenzo JA. 2002. 1,25(OH)2 vitamin D3- stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. J Immunol 169:2374-2380.
23. Liu J, Yang H, Liu W, Cao X, Feng X. 2005. Sp1 and Sp3 regulate the basal transcription of receptor activator of nuclear factor kappa B ligand gene in osteoblasts and bone marrow stromal cells. J Cell Biochem 96:716-727. (Pubitemid 41567543)
24. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell RG, Rogers MJ. 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589.
25. Mann V, Hobson EE, Li B, Stewart TL, Grant SF, Robins SP, Aspden RM, Ralston SH. 2001. A col1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest 107:899-907.
26. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, Morinaga T, Toyama Y, Yabe Y, Higashio K, Suda T. 1998. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 246:199-204.
27. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H. 2000. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biphys Res Commun 275:768-775.
28. Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K. 2005. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Biochem Biophys Res Commun 328:91-97.
29. Oikawa A, Kobayasi M, Okamatsu y, Shinki T, Kamijo R, Yamamoto M, Hasegawa K. 2007. Mitogen-activated protein kinases mediate interleukin 1β-induced receptor activator of nuclear factor-KB ligand expression in human periodontal ligament cells. J Periodontal Res 42:367-376.
30. Oyajobi BO. 2007. Multiple myeloma/hypercalcemia. Arthritis Res Ther 9(Suppl 1): S4.
31. 1-VCAM-1 interaction. Bone 23(5) Suppl 1:S180.
32. Pacifici R. 1998. Cytokines, estrogen and postmenopausal osteoporosis- the second decade. Endocrinology 139:2659-2661.
33. Patel SA, Sherman L, Munoz J, Rameshwar P. 2008. Immunological properties of mesenchymal stem cells and clinical implications. Arch Immunol Ther Exp 56:1-8.
34. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y. 2001. Multiple myeloma disrupts the trance/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Nat Acad Sci 98:11581-11586.
35. Raisz LG. 1997. The osteoporosis revolution. Ann Int Med 126:458-462.
36. Roux S, Mariette X. 2004. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappa B) and RANK ligand expression. Leuk Lymphoma 45:1111-1118. (Pubitemid 38584891)
37. Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand JP, Milgrom E, Mariette X. 2002. RANK (receptor activator of nuclear factor-KB) and RANKL expression in multiple myeloma. Br J Haematol 117:86-92.
38. Russell RGG, Watts N, Ebetino FH, Rogers MJ. 2008. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporosis Int 19:733-759.
39. Salmon SE, Durie BG. 1978. Clinical staging and new therapeutic approaches in multiple myeloma. Recent results. Cancer Res 65:12-20. (Pubitemid 9109844)
40. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. 2000. Bisphosphonates induce apoptosis in human breast cancer cells. Br J Cancer 82:1459-1468. (Pubitemid 30175914)
41. Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher PI. 1997. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity. Br J Haematol 98:665-672.
42. Shipman CM, Vanderkerken K, Rogers MJ, Lippitt JM, Asosingh K, Hughes DE, Van Camp B, Russell RG, Croucher PI. 2000. The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. Br J Haematol 111:283-286.
43. Solit DB, Garreway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. 2006. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362.
44. Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M. 2006. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 224:462-471.
45. Srivastava S, Weitzmann MN, Kimble RB, Rizzo M, Zahner M, Milbrandt J. 1998. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation with Sp1. J Clin Invest 102:1850-1859.
46. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A. 2002. Osteoprotegerin is bound internalized and degraded by multiple myeloma cells. Blood 100:3002-3007.
47. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC. 2006 Role of B-cell activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66:6675-6682.
48. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC. 2007. Targeting MEK induces myeloma-cells cytotoxicity and inhibits osteoclastogenesis. Blood 110:1656-1663.
49. Takahashi-Tezuka M, Hibi M, Fujitani Y, Fukada T, Yamaguchi T, Hirano T. 1997. Tectyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK. Oncogene 14:2273-2282. (Pubitemid 27260719)
50. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115:282-290.